The Harrington Discovery Institute at University Hospitals (UH) in Cleveland, Ohio, recently announced the 2016 recipients of its Harrington Scholar-Innovator Awards, given in support of physician-scientists whose discovery research holds promise in advancing the standard of patient care. Among this year’s winners is Stanley N. Cohen, MD, from Stanford University, who received $700,000…
Ionis Pharmaceuticals, Inc. — formerly Isis Pharmaceuticals — announced the U.S. Food and Drug Administration (FDA) has approved its Orphan Drug Designation application for IONIS-HTTRx as a potential treatment of Huntington’s disease (HD). Ionis’ IONIS-HTTRx is a generation 2.0+ antisense drug developed to treat HD by reducing the production of all forms of the huntingtin…
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company advancing treatments for depression, cancer, and diseases like Huntington’s that involve the central nervous system, announced that it has secured exclusive worldwide commercial rights to three patent-pending stem-cell technologies from the University Health Network (UHN) of Canada. The technologies were discovered and developed at…
Oxford Finance, LLC announced that it has finished helping Chosen Healthcare, which operates expert nursing facilities for a variety of illnesses including Huntington’s disease, to recapitalize and position itself for future growth. Chosen Healthcare owns 22 expert nursing facilities and one assisted living facility in Indiana, Iowa and Texas. The organization focus is…
A group of researchers from the University of Florida Health have discovered new information about Huntington’s disease, namely that the gene causing this severe disorder causes an unforeseen accumulation of “cocktails” of mutant proteins (RAN proteins) in the brain. These newly identified mutant proteins damage neurons and build up in areas…
Researchers at the German Center for Neurodegenerative Diseases (DZNE) in Bonn have tested a new substance that may lead to a prototype for the development of drugs to treat Alzheimer’s disease and other tauopathies, including Huntington’s disease. The substance, anle138b, improved symptoms in mice and showed an improvement in their cognition,…
The Hereditary Disease Foundation (HDF) recently hosted a celebratory night, gathering close to 200 recognized names and raising $1.2 million to support its efforts. The “Celebration of Discovery” Symposium and Dinner took place Monday, Nov. 9, at the Metropolitan Club in New York. The foundation, focused on finding cures to life-shattering…
Psychiatric manifestations develop more often than previously thought in Huntington’s disease prodrome, according to findings of a recent study published in The American Journal of Psychiatry. Moreover, it appears that symptoms also increase with disease severity. Early features of Huntington’s disease can include personality changes, mood swings,…
The Rutgers’ Human Genetics Institute of New Jersey, home to RUCDR Infinite Biologics — the world’s largest university-based biorepository — announced it has received a five-year grant from the National Institute of Neurological Disorders and Stroke (NINDS). The $6 million funding will allow Rutgers to assume management of the NINDS stem cell repository,…
While moving is normal to healthy people, making even the smallest movements may seem a difficult task for those who suffer from movement disorders such as Huntington’s disease. The Houston Methodist Sugar Land Hospital is spreading awareness about these types of conditions and their proper treatment, the importance of seeking professional help…
Get regular updates to your inbox.